PFI-3   Click here for help

GtoPdb Ligand ID: 7915

Synonyms: compound 16 [PMID: 27115555] | IN2080 | PF-06687252 [1] | PFI 3
PDB Ligand
Compound class: Synthetic organic
Comment: PFI-3 is a selective chemical probe for SMARCA bromodomains, including SMARCA2, SMARCA4 and PB1(5) (PBRM1) bromodomains. PFI-3 is one of the compounds contained in the Structural Genomics Consortium's Epigenetics Probes Collection. It's discovery, selectivity profile and pharmacological characterization is reported in [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

PFI-3 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 56.67
Molecular weight 321.15
XLogP 4.2
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C(c1ccccc1O)C=CN1CC2CC1CN2c1ccccn1
Isomeric SMILES O=C(c1ccccc1O)/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1
InChI InChI=1S/C19H19N3O2/c23-17-6-2-1-5-16(17)18(24)8-10-21-12-15-11-14(21)13-22(15)19-7-3-4-9-20-19/h1-10,14-15,23H,11-13H2/b10-8+/t14-,15-/m1/s1
InChI Key INAICWLVUAKEPB-QSTFCLMHSA-N
No information available.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
SMARCA2 and SMARCA4 are the central ATPase components of mammalian SWItch/Sucrose Non-Fermentable (SWI/SNF) complexes which play a key role in cell differentiation and proliferation. The human analogue of SWI/SNF is the Polybromo, Brg1-Associated Factors (PBAF) complex which contains the polybromo-1 (PB1) protein along with SMARCA2 and SMARCA4. Genetic lesions of SWI/SNF complexes have been associated with cancer development. Both SMARCA2 and SMARCA4, and PB1 contain a C-terminal bromodomain. Inhibitors targeting these bromodomains are being sought as useful chemical probes for interrogating SWI/SNF mediated processes, potentially offering clues for the development of novel therapeutics.